HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dermablend

This article was originally published in The Rose Sheet

Executive Summary

Richard Scanlon to newly created position of exec VP and chief operating officer. Scanlon moves to the Carson Products subsidiary from Charles of the Ritz, where he served as VP of sales. He previously worked at Revlon and Dana Perfumes. Scanlon reports to Dermablend CEO Tim Hogan. Carson recently carved out Dermablend into a new subsidiary ("The Rose Sheet" Jan. 4, p. 3). Scanlon and Hogan both served as consultants to Carson during the acquisition of the brand from Johnson Products ("The Rose Sheet" June 22, 1998, p. 1). The execs will "focus on fundamentals and execution" of the corrective cosmetics brand and improve the firm's service levels to distributors and customers. The Dermablend franchise will also receive a "modest expansion," including additional shade offerings and a stronger product mix. Upcoming product launches include cleansers and moisturizers

Latest Headlines
See All
UsernamePublicRestriction

Register

RS006197

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel